Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 2Recurrence 1Gliosarcoma 1Glioma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 81Specimen Handling 80Cyclophosphamide 72pembrolizumab 61Nivolumab 53Radiotherapy 52fludarabine 43Cisplatin 42Biopsy 40Carboplatin 38Standard of Care 35Dexamethasone 31Radiation 30Bevacizumab 30Rituximab 29Surveys and Questionnaires 27Radiosurgery 26Doxorubicin 26Temozolomide 25Gemcitabine 25Cytarabine 25Blood Specimen Collection 25venetoclax 24Practice Guidelines as Topic 24Paclitaxel 24fludarabine phosphate 23Ipilimumab 21atezolizumab 20Vincristine 20Interviews as Topic 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lomustine × 30 days × Clear all
NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting
24 enrolled
CNS

Brain Neoplasms, Glioma

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡